FIELD: chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to chemistry and pharmaceutical industry, in particular to a pharmaceutical composition for treating congenital adrenal hyperplasia in a subject in a dosage form in the form of an oral solution containing: (a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine [compound of formula (I)]
or a pharmaceutically acceptable salt thereof; (b) one or more of a sweetener, an antioxidant and a flavoring agent; and (c) medium chain triglycerides. Also disclosed is a method of producing said pharmaceutical composition and use thereof for treating congenital adrenal hyperplasia in a subject.
EFFECT: group of inventions provides creating a dosage form of the compound of formula (I) in the form of an oral solution suitable for administration, for example, to pediatric patients.
160 cl, 44 dwg, 45 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CFR RECEPTOR ANTAGONISTS FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | 2015 |
|
RU2812318C2 |
| METHODS OF TREATING SJOGREN SYNDROME USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2824354C2 |
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| CFR RECEPTOR ANTAGONISTS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA | 2015 |
|
RU2718918C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| SOLID DOSAGE FORMS OF PALLBOCYCLOB | 2016 |
|
RU2686840C1 |
| INCREASE OF DRUG BIDOSTASTICITY AT THERAPY BY NALTREXONE | 2011 |
|
RU2640561C2 |
| INCREASE IN BIOAVAILABILITY OF DRUGS IN THERAPY WITH NALTREXONE | 2011 |
|
RU2781141C2 |
| GASTRO-RESISTANT DOSAGE FORMS FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE | 2018 |
|
RU2812901C2 |
| METHODS OF USING AGONISTS FXR | 2017 |
|
RU2737324C2 |
